Pfizer

News

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

News

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.

News

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

Oncology

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

News

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.